Merck KGaA

XTRA:MRK Rapport sur les actions

Capitalisation boursière : €60.7b

Merck KGaA Croissance future

Future contrôle des critères 1/6

Merck KGaA devrait augmenter ses bénéfices et son chiffre d'affaires de 8.9% et de 4.4% par an respectivement. Le BPA devrait croître de de 9% par an. Le rendement des capitaux propres devrait être 12.7% dans 3 ans.

Informations clés

8.9%

Taux de croissance des bénéfices

8.98%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices24.3%
Taux de croissance des recettes4.4%
Rendement futur des capitaux propres12.66%
Couverture par les analystes

Good

Dernière mise à jour05 Jul 2026

Mises à jour récentes de la croissance future

Recent updates

Mise à jour du récit • Jul 06

MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside

Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.
Mise à jour du récit • Jun 22

MRK: Life Science Tools Recovery Will Support Future Upside Potential

Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.
Mise à jour du récit • Jun 06

MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside

Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
Mise à jour du récit • May 23

MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside

Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.
Mise à jour du récit • Apr 30

MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside

The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
Mise à jour du récit • Apr 15

MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance

Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
Mise à jour du récit • Apr 01

MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside

Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.
Mise à jour du récit • Mar 18

MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside

Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.
Mise à jour du récit • Mar 04

MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside

Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.
Mise à jour du récit • Feb 18

MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential

Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.
Mise à jour du récit • Feb 03

MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential

Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.
Mise à jour du récit • Jan 20

MRK: Refined Earnings Outlook Points To Balanced Future Return Potential

Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.
Mise à jour du récit • Jan 06

MRK: Future Earnings Power And HPC Expansion May Support Upside

Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.
Mise à jour du récit • Dec 21

MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead

Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.
Mise à jour du récit • Dec 07

MRK: Margin Strength And AI Deal Will Drive Future Upside

Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.
Mise à jour du récit • Nov 23

MRK: New Leadership Change And AI Partnership Will Drive Shares Higher

Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.
Mise à jour du récit • Nov 03

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.
Mise à jour du récit • Oct 20

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.
Mise à jour du récit • Sep 04

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.
Article d’analyse • Jul 24

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
User avatar
Nouveau récit • Nov 24

AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights

Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.

Prévisions de croissance des bénéfices et des revenus

XTRA:MRK - Estimations futures des analystes et données financières antérieures (EUR Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202823,2683,2163,1754,95312
12/31/202722,0502,9072,9214,63913
12/31/202621,0562,5382,7124,56914
3/31/202620,9562,5322,4194,194N/A
12/31/202521,1022,6082,1453,932N/A
9/30/202521,2712,9562,1033,872N/A
6/30/202521,2192,8621,8003,813N/A
3/31/202521,3162,8182,1844,107N/A
12/31/202421,1562,7772,4204,586N/A
9/30/202420,9632,6962,1604,408N/A
6/30/202420,8702,6262,0524,205N/A
3/31/202420,8202,7221,9613,966N/A
12/31/202320,9932,8241,8973,784N/A
9/30/202321,4282,8931,9123,746N/A
6/30/202322,0613,0782,1984,042N/A
3/31/202322,3273,2422,3344,272N/A
12/31/202222,2323,3262,4914,259N/A
9/30/202221,7853,4732,7884,289N/A
6/30/202220,9523,3112,6584,204N/A
3/31/202220,2543,1882,7344,240N/A
12/31/202119,6873,0553,2344,616N/A
9/30/202119,0722,6893,1254,859N/A
6/30/202118,5462,7333,0734,562N/A
3/31/202117,7952,2782,7024,177N/A
12/31/202017,5341,9872,0023,477N/A
9/30/202017,3171,8841,6842,879N/A
6/30/202016,9241,4191,4982,640N/A
3/31/202016,7761,5491,7292,879N/A
12/31/201916,1521,292N/A2,856N/A
9/30/201915,6581,139N/A2,906N/A
6/30/201915,3541,118N/A2,706N/A
3/31/201915,096938N/A2,332N/A
12/31/201814,8361,071N/A2,219N/A
9/30/201814,5971,921N/A2,120N/A
6/30/201814,3642,218N/A2,147N/A
3/31/201814,3462,389N/A2,299N/A
12/31/201714,5172,548N/A2,696N/A
9/30/201714,6991,787N/A2,842N/A
6/30/201714,9061,628N/A3,152N/A
3/31/201715,0161,529N/A2,943N/A
12/31/201615,0241,629N/A2,518N/A
9/30/201614,6581,480N/A2,449N/A
6/30/201614,0541,387N/A2,253N/A
3/31/201613,4691,418N/A2,268N/A
12/31/201512,8451,109N/A2,195N/A
9/30/201512,3801,269N/A2,618N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MRK ( 8.9% par an) est supérieure au taux d'épargne ( 1.9% ).

Bénéfices vs marché: Les bénéfices de MRK ( 8.9% par an) devraient croître plus lentement que le marché German ( 17% par an).

Croissance élevée des bénéfices: Les bénéfices de MRK devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de MRK ( 4.4% par an) devrait croître plus lentement que le marché de German ( 6.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de MRK ( 4.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de MRK devrait être faible dans 3 ans ( 12.7 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/07/10 01:38
Cours de l'action en fin de journée2026/07/10 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Merck KGaA est couverte par 42 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Odile RundquistBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research
Charles PitmanBarclays